To ensure that protein production in our cells runs smoothly, the protein complex NAC slows down the rate of protein synthesis right at the start. An international research team with significant involvement of Konstanz biologists has now discovered what underlies this previously unknown function of NAC.

Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications Medicine introducing an Oxford Nanopore Technologies (ONT)-based method for detecting small RNA modifications in blood.

How modern medical technology can prevent serious consequences of surgical procedures is demonstrated by a recent internationally recognized scientific publication. The study “Validation of conductive resin as electrode material in neuromonitoring with 3D-printed probes” under the leadership of Drs. Kiese and Bucher was awarded at the ICST Conference in Japan and highlights a medical topic that is crucial for the quality of life of many people.

Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

Inflammation has to work fast against pathogens—but it can't get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this balancing act. Their work shows that cells use two different strategies to precisely control inflammatory genes and thus precisely regulate the inflammatory response.

Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.

In a joint study conducted by the DZHK sites in Heidelberg, Munich and Göttingen, researchers are deciphering how the spatial organisation of the genome in the heart determines genetic disease risks.